Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass

Osteoporosis International

Volumn 21, Issue 7, 2010, Pages 1215-1226

  Downs Jr , R W ^a   Moffett, A M ^b   Ghosh, A ^c   Cox, D A ^d   Dowsett, S A ^d   Harper, K ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b OB GYN Associates of Mid Florida   (United States)

^c JOHNSON AND JOHNSON   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Arzoxifene; Bone turnover markers; Osteoporosis; Safety; Selective estrogen receptor modulator

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ARZOXIFENE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; COLLAGEN TYPE 1; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PLACEBO; PROCOLLAGEN C PROTEINASE; RALOXIFENE; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; LIPID; PIPERIDINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE; BONE DENSITY; BONE MASS; BONE TURNOVER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOMETRIUM; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NIGHT SWEAT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; ADRENERGIC SYSTEM; BLOOD; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOMETRIUM; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERIDINES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES; VASOMOTOR SYSTEM;

EID: 79954480772     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1060-5     Document Type: Article

References (22)

1. Fabian CJ, Kimler BF, Anderson J et al (2004) Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10:5403-5417
2. Palkowitz AD, Glasebrook AL, Thrasher KJ et al (1997) Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl) ethoxy]phenoxy]-2-(4- hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 40:1407-1416
3. Sato M, Turner CH, Wang T et al (1998) LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1-7
4. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Inverstigators. JAMA 282:637-645
5. Siris ES, Harris ST, Eastell R et al (2005) Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 20:1514-1524
6. Suh N, Glasebrook AL, Palkowitz AD et al (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61:8412-8415
7. Suh N, Lamph WW, Glasebrook AL et al (2002) Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 8:3270-3275
8. Baselga J, Llombart-Cussac A, Bellet M et al (2003) Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 14:1383-1390
9. Buzdar A, O'Shaughnessy JA, Booser DJ et al (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007-1014
10. Deshmane V, Krishnamurthy S, Melemed AS et al (2007) Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 25:4967-4973
11. Münster PN, Buzdar A, Dhingra K et al (2001) Phase I study of a third-generation selective estrogen receptor modulator, LY353381. HCL, in metastatic breast cancer. J Clin Oncol 19:2002-2009
12. Bjarnason NH, Sarkar S, Duong T, Mitiak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930
13. Kurman RJ, Norris HJ (1994) Endometrial hyperplasia and related cellular changes. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract, 4th edn. Springer-Verlag, New York, pp 411-427
14. Johnston CC Jr, Bjarnason NH, Cohen FJ et al (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450
15. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationship between bone mineral density and incidence vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10
16. Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11-14
17. Eastell R, Barton I, Hannon RA, Chines A, Garnero P (2003) Delmas PD Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
18. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592
19. de Valk-de Roo GW, Stehouwer CD, Meijer P et al (1999) Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993-3000
20. Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451
21. Barrett-Connor E, Mosca L, Collins P, Raloxifene Use for The Heart (RUTH) Trial Investigators et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
22. Barrett-Connor E, Grady D, Sashegyi A et al (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857